Effect of irbesartan monotherapy compared with ACE inhibitors and calcium-channel blockers on patient compliance in essential hypertension patients: A multicenter, open-labeled, three-armed study

Blood Pressure

Volumn 14, Issue SUPPL.1, 2005, Pages 23-31

  Koylan, Nevres ^a   Acarturk, Esmeray ^b   Canberk, Aykan ^a   Caglar, Nail ^c   Caglar, Sali ^d   Erdine, Serap ^e   Guneri, Sema ^f   Ilerigelen, Baris ^e   Kabakci, Giray ^d   Onder, Remzi ^g   Sagkan, Olcay ^h   Buyukozturk, Kemalettin ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b CUKUROVA UNIVERSITY   (Turkey)

^c ANKARA UNIVERSITY   (Turkey)

^d HACETTEPE UNIVERSITY   (Turkey)

^e ISTANBUL UNIVERSITY   (Turkey)

^f DOKUZ EYLUL UNIVERSITY   (Turkey)

^g EGE UNIVERSITY   (Turkey)

^h ONDOKUZ MAYIS UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

ACE inhibitors; Angiotensin II receptor antagonists; Calcium channel blockers; Compliance; Essential hypertension; Irbesartan

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IRBESARTAN; ANTIHYPERTENSIVE AGENT; BIPHENYL DERIVATIVE; CALCIUM CHANNEL; TETRAZOLE DERIVATIVE;

ADULT; ANKLE EDEMA; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIZZINESS; DOSE CALCULATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER; XEROSTOMIA; AGED; BLOOD PRESSURE; COMPARATIVE STUDY; HYPERTENSION; METABOLISM; MIDDLE AGED; TIME;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CONSTIPATION; FEMALE; HEADACHE; HEARTBURN; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NAUSEA; PATIENT COMPLIANCE; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; XEROSTOMIA; AGED; CALCIUM CHANNELS;

EID: 22544464181     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08038020510040649     Document Type: Article

References (26)

1. Murray CJL, Lopez AD. Evidenced-based healthy policy: Lessons learned from the global burden of disease study. Science. 1996;274:740-743.
2. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
3. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis. 2001;156:1-10.
4. Mahley RW, Palaoglu KE, Atak Z, Dawson-Pepin J, Langlois AM, Cheung V, et al. Turkish Heart Study: Lipids, lipoproteins and apolipoproteins. J Lipid Res. 1995;36:839-859.
5. Sonmez HM, Basak O, Camci C, Baltaci R, Karazeybek HS, Yasgan F, et al. The epidemiology of elevated blood pressure as an estimate for hypertension in Aydin, Turkey. J Hum Hypertens. 1999;13:399-404.
6. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol and stoke in Eastern Asia. Lancet. 1998;352:1801-1807.
7. Guidelines Subcommitee. 1999 World Health Organization-Internal Society guidelines for the management of hypertension. J Hypertens. 1999;17:151-183.
8. Cazaubon C, Gougat J, Bousquiet F, Guiraudou P, Gayraud R, Lacour C, et al. Pharmacological characterization of SR47436, a new nonpeptide AT1 subtype angiotensin II antagonist. J Pharmacol Exp Ther. 1993;265:826-834.
9. Necciari J, Denolle T, Le Coz F, Donazollo Y, Pastor G, Sissman J. Pharmacokinetics of SR 47436 (BMS-186295), a new angiotensin II antagonist in man. J Hypertens. 1994; 12:88.
10. Ribstein J, Sissman J, Picard A, Bouroudian M, Mimran A. Effects of the angiotensin SR47436 (BMS-186295) on the pressor response to exogenous angiotensin II and the renin-angiotensin system in sodium replete normal subjects. J Hypertens. 1994;12:131.
11. Fogari R, Ambrosoli S, Corradi L, Degli Esposti E, Mos L, Nami R, et al., on behalf of the Irbesartan Multicenter Investigators' Group, 24 hour blood pressure control by oncce-daily administration of irbesartan assesed by ambulatory blood pressure monitoring. J Hypertens. 1997; 15:1511-1518.
12. Man in't Veld A. Clinical overview of irbesartan: Expanding the therapeutic window in hypertension. J Hypertens. 1997;15 Suppl 7:S27-S33.
13. Kochar M, Guthrie R, Triscari J, Kassler-Taub K, Reeves RA. Matrix study of irbesartan with hydroclorothiazide in mild-to-moderate hypertension. Am J Hypertens. 1999; 12:797-805.
14. Raskin P, Guthrie R, Flack JM, Reeves RA, Saini R, The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide. J Hum Hypertens. 1999;13:683-687.
15. Littlejohn T III, Saini R, Kassler-Taub K, Chrysant SG, Marbury T. Long-term safety and hypertensive efficacy of irbesartan: Pooled result of five open-label studies. Clin Exp Hypertens. 1992;21:1273-1295.
16. Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E, for the Irbesartan/Losartan Study Investigators, Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens. 1998;11:445-453.
17. Oparil S, Guthrie R, Lewin AJ, Marbury T, Reilly K, Triscari J, Witcher JA, on behalf of the Irbesartan/Losartan Study Investigators, An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers irbesartan and losartan. Clin Ther. 1998; 20:398-409.
18. Mancia G, Korlipara K, van Rossum P, Villa G, Silvert B, Gressin V. Irbesartan results in superior blood pressure reduction vs valsartan. J Hypertens. 2000;18:S208.
19. Mimran A, Ruilope L, Nys M, Kassler-taub K, Osbakken M. A randomised, doubled-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens. 1998;3:203-208.
20. Lacourciè Y. A multicenter, randomised, doubled-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged ≥ 65 years with mild to moderate hypertension. Clin Ther. 2000;22:1213-1224.
21. Stumpe KO, Haworth D, Hoglund C, Kerwin L, Martin A, Simon T, et al. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. Blood Press. 1998;7:31-37.
22. Sica DA, Marino MR, Hammett JL, Ferriera I, Gehr TWB, Ford NF. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. Clin Pharmacol Ther. 1997;62:610-618.
23. Mariano MR, Langenbacher KM, Raymond RH, Ford NF, Lasseter KC. Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis. J Clin Pharmacol. 1998;38:347-356.
24. Hasford J, Mimran A, Simons W. Irbesartan compliance evaluation (ICE): A population-based European study of persistence with initial antihypertensive therapy. In: Abstracts of the Satellite Symposia held at the 2nd International Forum on Agiotensin II Receptor Antagonism in Monte-Carlo, Monaco, 24-26 January 2001, Abstract S-III.3.
25. Guthrie R, Saini R, Herman T, Pleskow W, Sprecher D, Collins G, for the Multicenter Investigators, Efficacy and tolerability of irbesartan, an angiotensin II receptor antagonist, in primary hypertension: A doubled-blind, placebo-controlled, dose-titration study. Clin Drug Invest. 1998;15:217-227.
26. Go LRT, for the Philippine Aprovel Clinical Trial (PACT) Investigators. A multicenter, randomised, open label comparative study on irbesartan and felodipine in the treatment of hypertension among Filipino patients. PJC. 2000;28: 245-251.